AUSTIN, Texas, June 26, 2019 /PRNewswire/ -- Elios
Therapeutics, a biopharmaceutical company developing innovative
autologous, particle-delivered, dendritic cell cancer vaccines,
today announced the appointment of Phillip
Johnson as chief financial officer, effective immediately.
Mr. Johnson brings more than 25 years of financial and operational
leadership experience in both publicly traded and private
companies.
"We are delighted to welcome Phil to Elios," said Buddy Long, chief executive officer of Elios
Therapeutics. "Phil is a seasoned healthcare and financial
executive with a distinguished track record of building commercial
opportunities, raising capital and negotiating business development
transactions. His range of industry expertise and leadership skills
will serve us well as we advance our leading personalized
therapeutic cancer vaccine, TLPLDC (tumor lysate, particle-loaded,
dendritic cell vaccine), through clinical trials and into
commercialization for the prevention of disease recurrence in
patients with high-risk melanoma."
"I am thrilled to join Elios Therapeutics at this exciting time
in the Company's growth and development," said Phillip Johnson. "Elios has a truly innovative
immuno-oncology platform with potential applicability across a
broad range of tumor types. I look forward to working with the
management team to advance the program and further Elios' mission
of developing next-generation immunotherapies that may make a
meaningful difference in the lives of patients, caregivers and
physicians."
Mr. Johnson joins Elios after having served as an executive and
consultant for a number of publicly traded, privately held,
private equity and pre-IPO companies, developing strategy and
leading efforts to support fundraising, acquisitions, deal
structures, growing finance functions, and improving working
capital. Over the course of his career, Mr. Johnson has
provided companies with more than $850M in debt and equity financing to provide
sound financial footing and substantial growth – including the
development of corporate environments that have delivered
shareholder returns ranging from 50 to 1,700 percent.
Prior to consulting, Mr. Johnson served as chief financial
officer for Xeris Pharmaceuticals where he raised $65M in equity capital in Series B and C
financings. Prior to Xeris, Mr. Johnson was vice president
and corporate controller at ArthroCare Corporation, a publicly
traded private equity backed medical device company. During his
tenure at ArthoCare, Mr. Johnson helped lead the financial
reengineering activities that helped increase the Company's market
capital from $100M to $1.7B before it was acquired in May 2014. Earlier in his career, he served in
several key finance and leadership roles at Maverick Tube
Corporation, SAVI, LLC and Primary Webworks and completed two
commissions with Arthur Andersen and KPMG. Mr. Johnson is a
certified public accountant and holds a Bachelor of Arts in
Accounting from Furman University.
About TLPLDC
The TLPLDC vaccine is unique, both in how it is made and how it
is delivered. The vaccine is personalized, meaning it is made from
a patient's tumor and blood. Every patient's tumor has a unique
antigenic profile unlike any other, and dendritic cells found in
the blood are the most potent antigen presenting cells in the body.
Once TLPLDC is administered, it delivers the patient's complete
repertoire of tumor antigens to the immune system, creating a
dual innate and adaptive immune response, activating fighter T
cells, and triggering the immune system to recognize, and seek
out and destroy any cells containing the antigens and specific
mutations from their tumor.
Historically, autologous cancer vaccines have been rather
onerous to develop, sometimes taking months between the tumor
biopsy and administration. Elios has simplified the process so the
time from resection to injection is approximately two weeks. This
makes the vaccine highly feasible and easy for community and
academic oncologists to adopt into their practices.
TLPLDC is currently being studied as a monotherapy and in
combination with standard-of-care checkpoint inhibitor therapies in
a Phase IIb clinical trial for the treatment of late-stage melanoma
at leading academic cancer centers in the
United States.
About Elios Therapeutics, LLC
Elios Therapeutics, LLC, is a biopharmaceutical company
developing a portfolio of innovative personalized therapeutic
cancer vaccines targeting unmet medical needs across a broad range
of tumor types. Elios' lead therapeutic candidate is the TLPLDC
(tumor lysate, particle-loaded, dendritic cell) vaccine, a
personalized therapeutic cancer vaccine that uses a proprietary
particle delivery system to stimulate the body's immune system to
recognize cancer cells as foreign pathogens and fight a patient's
specific cancer. For more information, please
visit www.eliostherapeutics.com.
Forward-Looking Statements
This document contains forward‐looking statements relating to
the Company's strategy, objectives, business development plans and
financial position. All statements other than statements of
historical facts included in this document, including, without
limitation, statements regarding the Company's future financial
position, strategy, anticipated investments, costs and results,
status and results of clinical trials, size of patient population,
plans, outcomes of product development efforts, and objectives of
management for future operations, may be deemed to be
forward‐looking statements. You can identify forward-looking
statements by words such as "anticipate," "believe," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "will," "would" or the negative of
those terms, and similar expressions that convey uncertainty or
future events or outcomes.
These forward‐looking statements involve known and unknown
risks, uncertainties, and other factors that may cause the
Company's actual results, performance, or achievements or industry
results to be materially different from those contemplated,
projected, forecasted, estimated or budgeted, whether expressed or
implied, by these forward‐looking statements. Given these risks and
uncertainties, investors should not place undue reliance on
forward‐looking statements as a prediction of actual results. None
of these forward‐looking statements constitutes a guarantee of the
future occurrence of such events or of actual results. These
statements are based on data, assumptions, and estimates that the
Company believes are reasonable.
The forward‐looking statements contained in this document are
made only as of the date hereof. Except as otherwise required by
law, the Company expressly disclaims any obligation or undertaking
to release publicly any updates of any forward-looking statements
contained in this document to reflect any change in its actual
results, assumptions, expectations or any change in events,
factors, conditions, or circumstances on which any forward‐looking
statement contained in this document is based.
Contacts:
Media Relations
Melyssa Weible
Elixir Health Public Relations
+1 (201) 723-5805
mweible@elixirhealthpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/elios-therapeutics-announces-appointment-of-phillip-johnson-as-chief-financial-officer-300874958.html
SOURCE Elios Therapeutics, LLC